Physician profile
Samuel Castillo
NPI 1467503672
$4,446.92
in general payments reported to CMS, 2019-2025
20 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $1,143 · 2021: $1,474 · 2022: $812 · 2023: $358 · 2024: $96.37 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,836.29 | 2020-2025 | Xifaxan |
| Janssen Biotech, INC. | $508.83 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $404.63 | 2019-2022 | |
| Celgene Corporation | $302.59 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $268.31 | 2019-2022 | |
| Gilead Sciences, INC. | $267.07 | 2020-2025 | |
| Braintree Laboratories, INC. | $130.67 | 2019-2022 | |
| Pfizer INC. | $125.50 | 2022-2023 | |
| Madrigal Pharmaceuticals | $118.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $111.43 | 2019-2021 | |
| Alfasigma USA, INC. | $83.71 | 2020-2022 | |
| Boston Scientific Corporation | $69.96 | 2024-2025 | Exalt Model D, Captivator II |
| Ironwood Pharmaceuticals, INC | $52.75 | 2019-2020 | |
| Ardelyx, INC. | $41.78 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $33.58 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $28.07 | 2019 | |
| Redhill Biopharma INC. | $26.96 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.51 | 2023 | |
| Lucid Diagnostics INC. | $13.05 | 2023 | |
| Romark Laboratories, Lc | $8.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.